

Ivo Abraham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4896847/publications.pdf>

Version: 2024-02-01

87
papers

1,456
citations

361296

20
h-index

377752

34
g-index

88
all docs

88
docs citations

88
times ranked

2037
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	1.3	112
2	The association of <i>BRCA1</i> and <i>BRCA2</i> mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. <i>Prostate</i> , 2019, 79, 880-895.	1.2	100
3	<i>BRCA1</i> and <i>BRCA2</i> Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1178-1189.	3.0	92
4	Real-life Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1362-1370.e2.	2.0	83
5	The cost of blood transfusion in Western Europe as estimated from six studies. <i>Transfusion</i> , 2012, 52, 1983-1988.	0.8	78
6	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016, 24, 911-925.	1.0	62
7	Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. <i>Future Oncology</i> , 2014, 10, 1599-1609.	1.1	50
8	Development of a biomarker mortality risk model in acute respiratory distress syndrome. <i>Critical Care</i> , 2019, 23, 410.	2.5	50
9	Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study. <i>Clinical Therapeutics</i> , 2015, 37, 842-857.	1.1	48
10	Clinical safety of biosimilar recombinant human erythropoietins. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 819-840.	1.0	46
11	Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 235-246.	1.0	42
12	Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2017, 20, 1083-1093.	1.0	30
13	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 16-25.	2.0	28
14	Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients. <i>Psycho-Oncology</i> , 2020, 29, 617-631.	1.0	27
15	Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2017, 17, 385.	1.3	26
16	Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. <i>Journal of Medical Economics</i> , 2017, 20, 345-352.	1.0	25
17	Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. <i>Future Oncology</i> , 2017, 13, 2285-2295.	1.1	25
18	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	2.0	25

#	ARTICLE	IF	CITATIONS
19	Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 184-197.	2.0	23
20	Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). <i>Journal of Geriatric Oncology</i> , 2017, 8, 86-95.	0.5	22
21	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. <i>Journal of Medical Economics</i> , 2019, 22, 1202-1209.	1.0	22
22	Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2017, 25, 1819-1828.	1.0	20
23	Measurement of fatigue: Comparison of the reliability and validity of single-item and short measures to a comprehensive measure. <i>International Journal of Nursing Studies</i> , 2017, 65, 35-43.	2.5	19
24	Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. <i>Journal of Medical Economics</i> , 2020, 23, 28-36.	1.0	19
25	Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. <i>Journal of Medical Economics</i> , 2020, 23, 856-863.	1.0	17
26	Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. <i>Vascular Health and Risk Management</i> , 2011, 7, 209.	1.0	16
27	Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 198-200.	2.0	15
28	Proposed guidance on cost-avoidance studies in pharmacy practice. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1559-1567.	0.5	15
29	Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 327-334.	1.0	13
30	Psychometric comparison of single-item, short, and comprehensive depression screening measures in Korean young adults. <i>International Journal of Nursing Studies</i> , 2016, 56, 71-80.	2.5	12
31	Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. <i>Pharmacoeconomics</i> , 2018, 36, 1333-1343.	1.7	12
32	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day ($\leq 24\text{h}$), $\leq 72\text{h}$, and $\leq 72\text{h}$): findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2019, 27, 2301-2312.	1.7	12
33	Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association. <i>International Journal of Pharmacy Practice</i> , 2021, 29, 21-28.	0.3	12
34	Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. <i>Pharmacoeconomics</i> , 2017, 35, 83-95.	1.7	11
35	Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Adherent vs Nonadherent Hypertensive Patients: Pooled Analysis of 6 Studies With 14,646 Evaluable Patients. <i>Journal of Clinical Hypertension</i> , 2013, 15, 663-673.	1.0	10
36	Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction. <i>Pharmacological Research</i> , 2020, 160, 105053.	3.1	10

#	ARTICLE	IF	CITATIONS
37	Methods used to attribute costs avoided from pharmacist interventions in acute care: A scoping review. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1576-1590.	0.5	10
38	Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study. <i>Journal of Infection and Public Health</i> , 2021, 14, 726-733.	1.9	10
39	When a Whole Practice Model Is the Intervention: Developing Fidelity Evaluation Components Using Program Theory-Driven Science for an Integrative Medicine Primary Care Clinic. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-11.	0.5	9
40	Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies. <i>Leukemia Research</i> , 2017, 57, 104-108.	0.4	9
41	Integrative medicine primary care: assessing the practice model through patients'™ experiences. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 490.	3.7	9
42	Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. <i>Pharmacoeconomics</i> , 2018, 36, 1273-1284.	1.7	9
43	Pricing methods in outcome-based contracting: 3: reference-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1230-1236.	1.0	9
44	Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium. <i>British Journal of General Practice</i> , 2015, 65, e9-e15.	0.7	8
45	Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. <i>Journal of Medical Economics</i> , 2018, 21, 606-609.	1.0	8
46	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. <i>Leukemia Research</i> , 2019, 85, 106215.	0.4	8
47	Pricing methods in outcome-based contracting: 1: cost effectiveness analysis and cost-utility analysis-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1215-1222.	1.0	8
48	Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 4867-4874.	1.0	8
49	Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e820-e831.	0.2	8
50	Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-9.	0.5	7
51	Pricing methods in outcome-based contracting: 2: willingness-to-pay-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1223-1229.	1.0	7
52	Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2021, 106, 106591.	0.4	7
53	Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US. <i>Blood</i> , 2018, 132, 4776-4776.	0.6	7
54	Physicians'™ perceptions, expectations, and experiences of clinical pharmacists in Jordan-2017. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1193-1201.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 \hat{I} 's). <i>Journal of Medical Economics</i> , 2020, 23, 1266-1272.	1.0	6
56	Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. <i>Value in Health</i> , 2022, 25, 1685-1695.	0.1	6
57	Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. <i>Journal of Medical Economics</i> , 2021, 24, 598-606.	1.0	5
58	Pricing methods in outcome-based contracting: \hat{I} 4: safety-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1237-1245.	1.0	4
59	Pricing methods in outcome-based contracting: \hat{I} 5: risk of efficacy failure-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1246-1255.	1.0	4
60	Pricing methods in outcome-based contracting: \hat{I} 6: adherence-based pricing. <i>Journal of Medical Economics</i> , 2020, 23, 1256-1265.	1.0	4
61	Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. <i>Future Oncology</i> , 2021, 17, 3485-3497.	1.1	4
62	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 319-329.	0.4	3
63	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 205-217.	1.0	3
64	Evaluation of Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism for Inherited Thrombophilia Disorders. <i>Blood</i> , 2016, 128, 5007-5007.	0.6	3
65	Differential Agnostic Effect Size Analysis of Lumbar Stenosis Surgeries. <i>International Journal of Spine Surgery</i> , 2022, 16, 318-342.	0.7	3
66	Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. <i>Future Oncology</i> , 2022, 18, 2381-2390.	1.1	3
67	Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective. <i>Critical Care Medicine</i> , 2020, 48, e906-e911.	0.4	2
68	<i>Journal of Medical Economics</i> in review: the best of 2021. <i>Journal of Medical Economics</i> , 2022, 25, 282-286.	1.0	2
69	Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence. <i>Expert Review of Anti-Infective Therapy</i> , 2022, , 1-11.	2.0	2
70	Melanoma Epidemiologyâ€™Pivoting to Low- and Middle-Income Countries. <i>JAMA Dermatology</i> , 2022, 158, 489.	2.0	2
71	A Proposed Personalized Spine Care Protocol (SpineScreen) to Treat Visualized Pain Generators: An Illustrative Study Comparing Clinical Outcomes and Postoperative Reoperations between Targeted Endoscopic Lumbar Decompression Surgery, Minimally Invasive TLIF and Open Laminectomy. <i>Journal of Personalized Medicine</i> , 2022, 12, 1065.	1.1	2
72	Comparing incomparables with the wrong analytics: Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis. <i>Thrombosis Research</i> , 2019, 178, 110-111.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Response to Katona et al. Journal of the National Cancer Institute, 2019, 111, 524-525.	3.0	1
74	Safety and efficacy of direct oral anticoagulants (DOAC) in cancer patients: Meta-analysis of randomized controlled trials (RCT).. Journal of Clinical Oncology, 2017, 35, e18264-e18264.	0.8	1
75	Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. Expert Opinion on Biological Therapy, 2021, 21, 1647-1653.	1.4	1
76	COPD Hospitalization Risk Increased with Distinct Patterns of Multiple Systems Comorbidities Unveiled by Network Modeling. AMIA ... Annual Symposium proceedings, 2014, 2014, 855-64.	0.2	1
77	Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-14.	0.5	1
78	A Differential Clinical Benefit Examination of Full Lumbar Endoscopy vs Interspinous Process Spacers in the Treatment of Spinal Stenosis: An Effect Size Meta-Analysis of Clinical Outcomes. International Journal of Spine Surgery, 2022, 16, 102-123.	0.7	1
79	Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study. Journal of Geriatric Oncology, 2013, 4, 196-201.	0.5	0
80	Clinical Failure Rates With and Without Atypical Coverage in Hospitalized Adults With Community-Acquired Pneumonia: A Meta-analysis. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
81	Letter to the Editor: When Claiming a U-shaped Association between Uric Acid Levels and Major Adverse Cardiac Events, Perhaps Show the Evidence?. Journal of Korean Medical Science, 2018, 33, e50.	1.1	0
82	Why health policies should be transnational: A case for East Asia Pacific countries. International Journal of Risk and Safety in Medicine, 2019, 30, 101-125.	0.3	0
83	Evaluation of Efficacy and Safety of Direct Oral Anticoagulants (DOACS) in the Treatment of Venous Thromboembolism in Cancer Patients. Blood, 2016, 128, 5016-5016.	0.6	0
84	Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis. Journal of Infection and Public Health, 2022, 15, 1-6.	1.9	0
85	Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate. Blood, 2020, 136, 22-22.	0.6	0
86	Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma. Blood, 2020, 136, 24-25.	0.6	0
87	Child Maltreatment and the Ecosystem of Socioeconomic Inequities and Inequalities. JAMA Network Open, 2022, 5, e2221516.	2.8	0